Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials

Ophthalmology

Volumn 123, Issue 8, 2016, Pages 1716-1721

  Wykoff, Charles C ^a   Elman, Michael J ^b   Regillo, Carl D ^c   Ding, Beiying ^d   Lu, Na ^d   Stoilov, Ivaylo ^d  

^a RETINA CONSULTANTS OF HOUSTON   (United States)

^b Elman Retina Group   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN; HEMOGLOBIN A1C; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CENTRAL RETINAL THICKNESS; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DISEASE DURATION; HUMAN; LONG TERM CARE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETIC RETINOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; BLOOD GLUCOSE; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84969256283     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.04.004     Document Type: Conference Paper

References (17)

1. 1 Ciulla, T.A., Amador, A.G., Zinman, B., Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26 (2003), 2653–2664.
2. 2 Early Treatment Diabetic Retinopathy Study Research Group, Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985), 1796–1806.
3. 3 Brown, D.M., Nguyen, Q.D., Marcus, D.M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120 (2013), 2013–2022.
4. 4 Elman, M.J., Aiello, L.P., Beck, R.W., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117 (2010), 1064–1077.e35.
5. 5 Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121 (2014), 2247–2254.
6. 6 Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119 (2012), 789–801.
7. 7 Simo, R., Sundstrom, J.M., Antonetti, D.A., Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37 (2014), 893–899.
8. 8 Aiello, L.P., Angiogenic pathways in diabetic retinopathy. N Engl J Med 353 (2005), 839–841.
9. 9 Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372 (2015), 1193–1203.
10. 10 Ip, M.S., Domalpally, A., Hopkins, J.J., et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130 (2012), 1145–1152.
11. 11 Lucentis Prescribing Information, 2015 Available at: http://www.gene.com/download/pdf/lucentis_prescribing.pdf Accessed August 11, 2015.
12. 12 Boyer, D.S., Nguyen, Q.D., Brown, D.M., et al. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 122 (2015), 2504–2513.
13. 13 Chen, E., Looman, M., Laouri, M., et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 26 (2010), 1587–1597.
14. 14 The Diabetic Retinopathy Clinical Research Network, Elman, M.J., Qin, H., et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs deferred laser treatment: 3-year randomized trial results. Ophthalmology 119 (2012), 2312–2318.
15. 15 Elman, M.J., Ayala, A., Bressler, N.M., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122 (2015), 375–381.
16. 16 The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
17. 17 Stratton, I.M., Kohner, E.M., Aldington, S.J., et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44 (2001), 156–163.